Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...
VK2735 is a wholly owned dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, for the potential treatment of ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
and glucose-dependent insulinotropic polypeptide (GIP). Currently, there are two approved GLP-1 and one combined GIP/ GLP-1 receptor agonists indicated for chronic weight management. The advent of ...
17hon MSN
Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.
New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback